Cargando…
Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site)
Cancer of unknown primary site(CUPs) is a metastatic syndrome with an unidentifiable primary tumor, even after extensive workup to seek the primary site. CUPs accounts for about 3%-5% of the total number of all cancer diagnoses worldwide. The current precision medicine era has reclassified patients...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805240/ https://www.ncbi.nlm.nih.gov/pubmed/36587212 http://dx.doi.org/10.1186/s12885-022-10472-z |
_version_ | 1784862298448330752 |
---|---|
author | Yang, HongLiang He, Feng Xu, Wen Cao, Zeng |
author_facet | Yang, HongLiang He, Feng Xu, Wen Cao, Zeng |
author_sort | Yang, HongLiang |
collection | PubMed |
description | Cancer of unknown primary site(CUPs) is a metastatic syndrome with an unidentifiable primary tumor, even after extensive workup to seek the primary site. CUPs accounts for about 3%-5% of the total number of all cancer diagnoses worldwide. The current precision medicine era has reclassified patients with CUPs into the favorable and unfavorable prognostic subset. In this study clinical characteristics and treatment of patients of CUPs were retropactively analysed. Thirty-two patients treated from July 2016 to October 2021 were included in the Affiliated Tumor Hospital of Tianjin Medical University(Tianjin, China).Common symptoms were anemia, fever, enlarged lymph nodes, abdominal pain, edema/multiple serous cavity effusion. Patients with good prognostic factors achieved good outcomes with treatment, conversely, patients with poor prognosis were generally treated empirically and had poorer outcomes. After anti-tumor treatment, the total effective rate was 41 percent(41% was the percentage of patients who achievedtumour respons). To the end of follow-up, after anti-tumor treatment, the median Overall Survival(OS) of patients was 5.4 months. |
format | Online Article Text |
id | pubmed-9805240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98052402023-01-01 Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site) Yang, HongLiang He, Feng Xu, Wen Cao, Zeng BMC Cancer Research Cancer of unknown primary site(CUPs) is a metastatic syndrome with an unidentifiable primary tumor, even after extensive workup to seek the primary site. CUPs accounts for about 3%-5% of the total number of all cancer diagnoses worldwide. The current precision medicine era has reclassified patients with CUPs into the favorable and unfavorable prognostic subset. In this study clinical characteristics and treatment of patients of CUPs were retropactively analysed. Thirty-two patients treated from July 2016 to October 2021 were included in the Affiliated Tumor Hospital of Tianjin Medical University(Tianjin, China).Common symptoms were anemia, fever, enlarged lymph nodes, abdominal pain, edema/multiple serous cavity effusion. Patients with good prognostic factors achieved good outcomes with treatment, conversely, patients with poor prognosis were generally treated empirically and had poorer outcomes. After anti-tumor treatment, the total effective rate was 41 percent(41% was the percentage of patients who achievedtumour respons). To the end of follow-up, after anti-tumor treatment, the median Overall Survival(OS) of patients was 5.4 months. BioMed Central 2022-12-31 /pmc/articles/PMC9805240/ /pubmed/36587212 http://dx.doi.org/10.1186/s12885-022-10472-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yang, HongLiang He, Feng Xu, Wen Cao, Zeng Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site) |
title | Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site) |
title_full | Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site) |
title_fullStr | Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site) |
title_full_unstemmed | Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site) |
title_short | Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site) |
title_sort | clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of cancer with unknown primary site) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805240/ https://www.ncbi.nlm.nih.gov/pubmed/36587212 http://dx.doi.org/10.1186/s12885-022-10472-z |
work_keys_str_mv | AT yanghongliang clinicalfeaturesofcancerwithunknownprimarysiteclinicalfeaturestreatmentprognosisofcancerwithunknownprimarysite AT hefeng clinicalfeaturesofcancerwithunknownprimarysiteclinicalfeaturestreatmentprognosisofcancerwithunknownprimarysite AT xuwen clinicalfeaturesofcancerwithunknownprimarysiteclinicalfeaturestreatmentprognosisofcancerwithunknownprimarysite AT caozeng clinicalfeaturesofcancerwithunknownprimarysiteclinicalfeaturestreatmentprognosisofcancerwithunknownprimarysite |